Azenosertib for platinum-resistant ovarian cancer with cyclin e1
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial tests a new pill called azenosertib (ZN-c3) for ovarian cancer that stopped responding to platinum chemotherapy. The drug targets tumors with high levels of the Cyclin E1 protein, and the goal is to see if it can shrink tumors or slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You have high-grade serous ovarian, fallopian tube, or primary peritoneal cancer.
- Your cancer must have grown back within 6 months of platinum chemotherapy (platinum-resistant).
- A lab test must show your tumor has a high level of a protein called Cyclin E1.
- You must have tried certain standard treatments like bevacizumab, a PARP inhibitor, or mirvetuximab if recommended by your doctor.
- You are in generally good health (able to do light work) and have measurable tumors.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new pill called INCB123667 for people with a type of ovarian cancer that has stopped responding to platinum chemotherapy. The goal is to see if the drug can shrink tumors or slow their growth.
This trial tests a new drug called azenosertib against standard chemotherapy for ovarian, fallopian tube, or peritoneal cancer that has come back after platinum-based treatment. The drug targets a specific protein (cyclin E1) found in some tumors and may help stop cancer cells from dividing.
This Phase 1 trial studies how well and how safely azenosertib (ZN-c3) works in people with advanced ovarian, fallopian tube, or peritoneal cancer. It may help by offering a new treatment option for cancers that don’t respond well to platinum chemotherapy (platinum-resistant).
This trial is testing an oral drug called azenosertib for a type of uterine cancer that has come back or spread. It aims to see if blocking a DNA repair pathway can shrink tumors or slow their growth.
This trial tests a new drug, AZD5335, against standard treatments (mirvetuximab soravtansine or chemotherapy) for women with platinum-resistant ovarian cancer. It aims to see if AZD5335 works better based on the level of a protein called FRα on your tumor cells.
This study tests a new drug (INCB123667) given as a pill, compared to standard chemotherapy, for people whose ovarian cancer has stopped responding to platinum-based treatments and whose tumor has high levels of a protein called Cyclin E1. The goal is to see if the new drug works better than standard chemo for this specific type of cancer.
Hear when a new High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.